Hürthle cell thyroid carcinoma metastatic to the sigmoid colon

Thyroid

Volumn 17, Issue 2, 2007, Pages 169-173

  Arnous, W ^a   Beltran, S ^a   Berger, N ^b   Bournaud, C ^a,d   Lifante, U C ^b   Peix, J L ^b   Giammarile, F ^c   Sassolas, G ^a   Borson Chazot, Françoise ^a,d  

^a HÔPITAL NEUROLOGIQUE   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; LEVOTHYROXINE; PENTETATE INDIUM IN 111; PENTETREOTIDE IN 111; RADIOACTIVE IODINE; SOMATOSTATIN RECEPTOR; THYROGLOBULIN;

ADULT; ANAMNESIS; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SURGERY; CASE REPORT; COLON RESECTION; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTIGRAPHY; SIGMOID CARCINOMA; THYROID CARCINOMA; THYROID PARAFOLLICULAR CELL; VISCERAL METASTASIS;

EID: 33847668038     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.0210     Document Type: Article

References (25)

1. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306.
2. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
3. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JR, Offord KP, Gorman CA 1988 Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67:501-508.
4. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G 2001 Survival and therapeutic modalities in patients with bone metastases in differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568-1573.
5. Benbassat CA, Mechlis-Frish S, Hirch D 2006 Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg 30:1088-1095.
6. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899.
7. Besic N, Hocevar M, Zgajnar J, Petric R, Pilko G 2006 Aggressiveness of therapy and prognosis of patients with Hürthle cell papillary thyroid carcinoma. Thyroid 16:67-72.
8. Decaussin M, Bernard MH, Adeleine P, Treilleux I, Peix JL, Pugeat M, Tourniaire J, Berger N 2002 Thyroid carcinomas with distant metastases: a review of 111 cases with emphasis on the prognostic significance of an insular component. Am J Surg Pathol 26:1007-1015.
9. Ruggiero FP, Frauenhoffer EE, Stack BC 2005 Papillary thyroid cancer with an initial presentation of abdominal and flank pain. Am J Otolaryngol 26:142-145.
10. Logani S, Baloch ZW, Snyder PJ, Weinstein R, LiVolsi VA 2001 Cystic ovarian metastasis from papillary thyroid carcinoma: a case report. Thyroid 11:1073-1075.
11. Benbassat CA, Mechlis-Frish S, Morgenstein S 2005 Hürthle cell carcinoma metastatic to uterus. Thyroid 15:1309.
12. Aguiar P, Agner C, Tavares F, Yamaguchi N. 2001 Unusual brain metastases from papillary thyroid carcinoma: case report. Neurosurgery 49:1008-1013.
13. Kouso H, Ikegami T, Ezaki T, Ishida T, Aimitsu S, Fujihara M, Mori M 2005 Liver metastasis from thyroid carcinoma 32 years after resection of the primary tumor: report of a case. Surg Today 35:480-482.
14. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID 1995 Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 80:2041-2045.
15. Hiltzik D, Carlson DL, Tuttle RM, Chai S, Ishill N, Shaha A, Shah JP, Singh B, Ghossein RA 2006 Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106:1286-1295.
16. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; the European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803.
17. Stokkel MP, Duchateau CS, Dragoiescu C 2006 The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 50:78-87.
18. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-(18F) fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505.
19. Giammarile F, Hafd Z, Bournaud C, Houzard C, Janier M, Desuzinges C, Itti R, Sassolas G, Borson-Chazot F 2003 Is FDG scintigraphy with non-dedicated PET useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no-detectable radioiodine uptake? Eur J Endocrinol 149:293-300.
20. Stokkel MP, Reigman HI, Verkooijen RB, Smit JW 2003 Indium-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose 1-131. J Cancer Res Clin Oncol 129:287-294.
21. Sarlis NJ, Gourgiotis L, Guthrie LC, Galen B, Skarulis MC, Shawker TH 2003 In-111-DTPA octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18FDG positron emission tomography and extensive conventional radiographic imaging. Clin Nucl Med 28:208-217.
22. Giammarile F, Houzard C, Bournaud C, Hafdi Z, Sassolas G, Borson-Chazot F 2004 Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of ocreotide scintigraphy in patients inpatients with negative high-dose radioiodine scans. Eur J Endocrinol 150:277-283.
23. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP 2005 Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46 Suppl 1:62S-66S.
24. Teunissen JJM, Kwekkeboom DJ, Kooij PPM, Bakker WH, Krenning EP 2005 Peptide receptor radionuclide therapy for non radioiodine avid differentiated thyroid carcinoma. J Nucl Med 46 suppl 1:107S-114S.
25. Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU, Haldemann A, Mueller-Brand J 2001 Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer. Nucl Med Commun. 22: 673-678.